LL-37 yog tib neeg tshuaj tua kab mob peptide thiab yog 37 amino acid peptide muab los ntawm C-terminal domain ntawm nws cov precursor protein hCAP-18 (tib neeg cationic antimicrobial protein 18). Nws ua lub luag haujlwm tseem ceeb hauv kev tiv thaiv hauv lub cev thiab nthuav tawm dav-spectrum antimicrobial kev ua haujlwm tawm tsam cov kab mob, fungi thiab kab mob. Ntxiv nrog rau nws cov tshuaj tiv thaiv kab mob, LL-37 koom nrog hauv kev tiv thaiv kab mob, kho qhov txhab, angiogenesis thiab kev tswj kab mob qog noj ntshav.Nws cov lus qhia yog ubiquitous ntawm neutrophils, epithelial hlwb thiab mucosal nto (xws li qhov chaw mos thiab daim tawv nqaij), uas nws ua hauj lwm raws li thawj kab ntawm kev tiv thaiv kab mob. Qhov tseem ceeb, nws cov dej num yog tswj hwm los ntawm kev ua haujlwm proteolytic (xws li los ntawm serine proteases) thiab ib puag ncig yam xws li vitamin D.
Cov yam ntxwv thiab Physicochemical Properties
LL-37, Antimicrobial Peptide:
Ib tsab ntawv code: LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES
Triple Letter Code:
Leu-Leu-Gly-Asp-Ph-Ph-Arg-Lys-Ser-Lys{{9} }Glu-Lys-Ile-Gly-Lys-Glu-Phe-Lys-Arg{{1 8}}Ile-Val-Gln-Arg-Ile-Lys-Asp-Phe-Leu{-Arg-Asn-Leu-Val-Pro-Arg-Thr-Glu-Ser
Molecular Luj: 4493.33
Txais yuav ib qho amphipathic -helix nrog peb lub npe:
Terminal: Mediates chemotaxis thiab kev ua haujlwm hemolytic.
C-terminal: Lub luag haujlwm rau kev cuam tshuam ntawm daim nyias nyias thiab kev tiv thaiv kab mob.
C-terminal tail: Pab tetramerization ntawm kev cuam tshuam nrog anionic biomolecules.
Stability thiab Charge Dynamics
Charge: Net +6 ntawm physiological pH enables electrostatic targeting ntawm microbial daim nyias nyias.
Thermal stability: Fibrillar tus kheej - sib dhos ntawm cov khoom tawg (piv txwv li, LL-37(17–29)) tiv taus degradation ntawm 60-80℃.
Protease kuj: Hydrophobic packing thiab polar kev sib cuam tshuam muab ib feem tsis kam rau host proteases.
Synthesissis Rtawm
Tshuaj Synthesis:
Khoom-theem peptide synthesis (SPPS) feem ntau yog siv los tsim LL-37 thiab nws cov khoom tawg (xws li LL-37(17–29)).
Qhov zoo: siab purity, yooj rau kev hloov kho cov qauv (xws li, mutagenesis rau kev kawm ua haujlwm).
Cov kev sib tw: Tus nqi siab rau loj- teev ntau lawm thiab tej zaum yuav muaj teeb meem misfolding.
Recombinant Expression:
Prokaryotic systems (xws li, E. coli) yog siv rau LL-37 ntau lawm, yuav tsum tau codon optimization thiab fusion tags kom tsis txhob muaj toxicity.
Qhov zoo: Tus nqi - zoo rau kev tsim khoom ntau.
Cov kev sib tw: Tshaj tawm- kev hloov pauv kev txhais lus (xws li, kev sib cais los ntawm fusion tags) thiab muaj peev xwm suav nrog lub cev tsim.
Biomimetic Tus Kheej -Assembly:
LL-37 fragments (piv txwv li, LL-37(17–29)) nws tus kheej sib sau ua ke rau hauv kev ua haujlwm fibrils, muab lub scaffold rau ruaj khov biomaterials .
Qhov zoo: Txhim kho cov tshuaj tiv thaiv kab mob thiab kev ruaj ntseg.
Cov kev sib tw: Tswj kev sib dhos ua kom muaj zog rau kev kho mob sib xws.
Daim ntawv thov thiab qhov tseem ceeb
Antimicrobial Therapy:
LL-37 txo qis cov kab mob fungal (xws li Candida albicans hauv vulvovaginal candidiasis) thiab cov kab mob kis los ntawm kev cuam tshuam cov membranes thiab modulating cytokines (xws li, nce IFN- thiab txo IL-10).
Mob Cancer Modulation:
Qhia tawm ob lub luag haujlwm: tiv thaiv- mob qog noj ntshav (xws li, inhibiting hepatocellular carcinoma proliferation ntawm transcriptomic regulation) thiab pro-tumorigenic teebmeem (xws li, txhawb cov tawv nqaij squamous cell carcinoma ntawm NF-κB/dbpA signaling).
Cov Kab Mob Hlwb:
Cov qib ntshav qis qis LL-37 cuam tshuam nrog kev ua rau muaj kev mob hnyav hauv cov neeg mob COPD, qhia txog nws lub luag haujlwm hauv kev tiv thaiv kab mob thiab vitamin D interplay.
Biomaterials thiab Drug Delivery:
Tus kheej- sib sau ua ke LL-37 fibrils qhia tau tias muaj peev xwm tiv thaiv cov kab mob tiv thaiv kab mob thiab cov neeg nqa tshuaj vim lawv qhov ruaj khov thiab tus nqi saum npoo (+25 mV).
Cov kev sib tw tam sim no
Dual functionality: Cov ntsiab lus-dependent pro-/anti-cov teebmeem qog ua rau nyuaj rau cov hom phiaj kho mob.
Synthesis limitations: SPPS thiab recombinant systems tawm tsam nrog tus nqi thiab tawm los.
Immunotoxicity: Overactivation ntawm kev tiv thaiv kab mob (xws li, mob hawb pob) yuav ua rau muaj kev mob tshwm sim.
Kev xav yav tom ntej
Peptide Engineering: Tsim kho mob qog noj ntshav- xaiv cov mutants (xws li, EGFR-binding domain truncations).
Nanocarrier Systems: Siv tus kheej- sib dhos fibrils rau kev tswj cov tshuaj tso tawm.
Kev sim tshuaj kho mob: Ua ntej koob tshuaj -kev tshawb fawb nce ntxiv hauv biofilm- ntsig txog kab mob thiab kab mob autoimmune .
LL-37 piv txwv txog kev sib koom ua ke ntawm kev tiv thaiv kab mob hauv lub cev thiab kho kho tshiab. Thaum nws cov tshuaj tua kab mob thiab cov tshuaj tiv thaiv kab mob tiv thaiv kab mob tuav cov lus cog tseg, cov kev sib tw hauv kev sib txuas, kev xaiv, thiab kev nyab xeeb xav tau kev daws teeb meem sib tham. Yav tom ntej kev nce qib pob khawm ntawm kev ua kom zoo dua qub, biomarker-coj coj xa tuaj, thiab kev lees paub kev txhais lus.
Cov ntaub ntawv
1. Tib neeg tshuaj tua kab mob peptide, LL-37, induces non-inheritable txo susceptibility rau vancomycin nyob rau hauv Staphylococcus aureus. Kev Tshaj Tawm Txog Kev Tshawb Fawb (2025).
2. LL-37 Antimicrobial Peptide, tib neeg. 药智通 (2024).
3. LL-37, antimicrobial peptide, tib neeg. ChemicalBook (2024).
4. LL-37 txhawb nqa daim tawv nqaij squamous cell carcinoma ntawm NF-κB/dbpA. Oncology Letters (2016).
5. LL-37 derivatives nrog vancomycin tawm tsam S. aureus. J. Tshuaj tua kab mob (2025).
6. LL-37 tshem tawm S. aureus biofilms. PLOS IB (2019).
7. LL-37 hauv hawb pob exacerbation. Kev Tshaj Tawm Txog Kev Tshawb Fawb (2017).
8. LL-37 nyob rau hauv autoimmunity thiab kis kab mob. Tshuaj tiv thaiv (2020).
9. Cov Txheej Txheem Kev Tiv Thaiv Kab Mob ntawm Tib Neeg Antimicrobial Peptide LL-37.Aqeel Ahmad [1], Mohammed Ali Mullah Fawaz[2]. PIB: 10.37881/1.63.
